PARIS (FRANCE) AND TARRYTOWN, NY - December 10, 2019 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced their intent to simplify their antibody collaboration for Kevzara ...

Using patient-derived B cells, Kling-Select facilitates the rapid detection of new antibodies and preserved viral epitopes.

Kling Bio has announced a new collaboration and licence option agreement with Sanofi to accelerate the discovery of neutralising antibodies using its proprietary B cell platform, Kling-Select.

Sanofi a nnounces €300 m illion collaboration with Blackstone Life Sciences to a dvance an i nnovative t reatment for m ultiple m yeloma. Investment will accelerate the overall Sarclisa ...

Within in the Sanofi antibody collaboration, LDL cholesterol reduction drug Praluent has seen a slow launch trajectory because of payer restrictions, but we think U.S. sales growth can rebound ...

Following the equity investment and strategic collaborations, a Sanofi representative will join Adagene ... the SAFEbody platform can be applied to a wide variety of antibody-based ...

Terms of the Collaboration As previously announced, under the terms of the collaboration agreement, for each of the three Sanofi designated immunology/inflammation targets, IGM will lead research ...

IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody formatSelection of IPH6101/SAR443 ...

Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today.

Sanofi will lead commercialisation of any successful product from the collaboration. U.S. profits will be split equally, while elsewhere Sanofi will take a share of 55 to 65 percent.

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...